nutch_noindex
CANCELAR
COVID-2019 Alert

Information about the 2019 Novel Coronavirus. Read the latest >

Información sobre el coronavirus 2019 (COVID-19). Aprenda más >

/nutch_noindex

Andrew Giustini, MD

  • No hay imagen

Especialidades médicas y/o especialidades quirúrgicas

Anesthesia

Trabajo y educación

Educación

Dartmouth Geisel School of Medicine Office of the Registrar, Lebanon, NH, 06/08/2014

Últimos años de residencia

Stanford University Pediatric and Anesthesiology Residency, Palo Alto, CA, 6/30/2019

Subespecialidad

Stanford University Pediatric Anesthesia Fellowship, Palo Alto, CA, 07/31/2020

Certificado(s) de especialidad

Anesthesia, American Board of Anesthesiology

Pediatrics, American Board of Pediatrics

Todo Publicaciones

Trends in Views of Articles Published in 3 Leading Medical Journals During the COVID-19 Pandemic. JAMA network open Giustini, A. J., Schroeder, A. R., Axelrod, D. M. 2021; 4 (4): e216459

View details for DOI 10.1001/jamanetworkopen.2021.6459

View details for PubMedID 33792734

Moyamoya disease in children and its anesthetic implications: A review PEDIATRIC ANESTHESIA Giustini, A. J., Stone, S. A., Ramamoorthy, C. 2020

View details for DOI 10.1111/pan.14001

View details for Web of Science ID 000568620600001

Association Between Citations, Altmetrics, and Article Views in Pediatric Research. JAMA network open Giustini, A. J., Axelrod, D. M., Lucas, B. P., Schroeder, A. R. 2020; 3 (7): e2010784

View details for DOI 10.1001/jamanetworkopen.2020.10784

View details for PubMedID 32687584

Moyamoya disease in children and its anesthetic implications: A review. Paediatric anaesthesia Giustini, A. J., Stone, S. A., Ramamoorthy, C. n. 2020; 30 (11): 119198

Abstract

Moyamoya disease is a rare, progressive cerebral vasculopathy which most commonly presents in the first and fourth decades of life. The mainstay of treatment is surgical revascularization; without treatment, most patients experience ischemic or hemorrhagic strokes. This report reviews moyamoya disease, its associated conditions, surgical treatment techniques, and anesthetic management of patients with moyamoya disease.

View details for DOI 10.1111/pan.14001

View details for PubMedID 33463884

Pediatric Postoperative Pulse Oximetry Monitoring During Transport to the Postanesthesia Care Unit Reduces Frequency of Hypoxemia. Joint Commission journal on quality and patient safety Caruso, T. J., Mokhtari, T. E., Coughlan, M. J., Wu, D. S., Marquez, J. L., Duan, M. n., Freeman, H. n., Giustini, A. n., Tweedy, M. n., Sharek, P. J. 2017; 43 (3): 14650

Abstract

The standard use of pulse oximetry during the transport of postoperative patients from the operating room (OR) to the postanesthesia care unit (PACU) is not routinely practiced. A study was conducted to determine if the frequency of hypoxemia on admission to the PACU decreased after implementation of routine use of transport pulse oximeters for postoperative patients being transferred to the PACU.In this prospective cohort study, which was conducted at an academic pediatric hospital, the primary outcome measure was the frequency of hypoxemic events on arrival to the PACU.A total of 506 patients in the preintervention phase and 597 in the postintervention phase met the inclusion criteria. Six hypoxemic events on arrival to the PACU were identified in preintervention phase versus zero in the postintervention period, p=0.009. Use of oxygen monitors during transport from the OR to the PACU increased from 0% to 100%, p<0.0001, in the postintervention phase. The median duration of unmonitored time during transport decreased from 272 seconds to 13 seconds, p<0.0001. Of the 605 patients who met the inclusion criteria for sustainment audits-conducted 18 months after the postimplementation evaluation-99.8% were transported to the PACU with a pulse oximeter, and there were zero reported hypoxemic patients on PACU admission.The routine use of portable oxygen monitoring when transferring patients from the OR to the PACU is a low-cost, noninvasive safety measure that should be considered at any institution performing pediatric general anesthesia.

View details for DOI 10.1016/j.jcjq.2016.12.001

View details for PubMedID 28334593

The effect of hypofractionated radiation and magnetic nanoparticle hyperthermia on tumor immunogenicity and overall treatment response Hoopes, P., Wagner, R. J., Song, A., Osterberg, B., Gladstone, D. J., Bursey, A. A., Fiering, S. N., Giustini, A. J., Ryan, T. P. SPIE-INT SOC OPTICAL ENGINEERING. 2017

Abstract

It is now known that many tumors develop molecular signals (immune checkpoint modulators) that inhibit an effective tumor immune response. New information also suggest that even well-known cancer treatment modalities such as radiation and hyperthermia generate potentially beneficial immune responses that have been blocked or mitigated by such immune checkpoints, or similar molecules. The cancer therapy challenge is to; a) identify these treatment-based immune signals (proteins, antigens, etc.); b) the treatment doses or regimens that produce them; and c) the mechanisms that block or have the potential to promote them. The goal of this preliminary study, using the B6 mouse - B16 tumor model, clinically relevant radiation doses and fractionation schemes (including those used clinically in hypofractionated radiation therapy), magnetic nanoparticle hyperthermia (mNPH) and sophisticated protein, immune and tumor growth analysis techniques and modulators, is to determine the effect of specific radiation or hyperthermia alone and combined on overall treatment efficacy and immunologic response mechanisms. Preliminary analysis suggests that radiation dose (10 Gy vs. 2 Gy) significantly alters the mechanism of cell death (apoptosis vs. mitosis vs. necrosis) and the resulting immunogenicity. Our hypothesis and data suggest this difference is protein/antigen and immune recognition-based. Similarly, our evidence suggest that radiation doses larger than the conventional 2 Gy dose and specific hyperthermia doses and techniques (including mNP hyperthermia treatment) can be immunologically different, and potentially superior to, the radiation and heat therapy regimens that are typically used in research and clinical practice.

View details for PubMedID 29515284